Abstract
No one has solved the riddle of how best to conduct long-term, blinded MS trials and, consequently, definitive evidence that treatment protects against progression in disability remains elusive. The report by Kappos et al.14 attempts to make the most of the imperfect world of extension trials, a methodology that has been used by others to provide similar insight on the value of prolonged treatment with glatiramer acetate.15